医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2015年
3期
457-460
,共4页
乳腺肿瘤/遗传学%乳腺肿瘤/病理学%启动区(遗传学)%甲基化%预后
乳腺腫瘤/遺傳學%乳腺腫瘤/病理學%啟動區(遺傳學)%甲基化%預後
유선종류/유전학%유선종류/병이학%계동구(유전학)%갑기화%예후
Breast Neoplasms/GE%Breast Neoplasms/PA%Promoter Regions (Genetics)%Meth-ylation%Prognosis
【目的】探讨乳腺癌易感基因PALB2启动子甲基化与乳腺癌临床病理特征、预后的关系。【方法】采用MSP法检测128例乳腺癌石蜡组织中PALB2启动子甲基化情况，分析其与乳腺癌临床病理特征及临床预后的相关性。【结果】128例乳腺癌中有淋巴结转移的患者中14．04％（8／57）检测出PALB2启动子甲基化，高于无淋巴结转移患者的2．82％（2／71），且差异具有显著性（ P ＜0．05）。PALB2启动子甲基化组的中位无瘤生存时间与中位总生存时间分别为50个月和51．5个月，无甲基化组的中位无瘤生存时间与总生存时间分别为54个月和88个月，两者相比较差异均具有显著性（ P ＜0．01）。乳腺癌患者预后相关因素分析提示N分期及PALB2启动子甲基化情况均是影响乳腺癌患者预后的独立危险因素。【结论】乳腺癌组织PALB2基因启动子甲基化情况与是否有淋巴结转移相关。与PALB2启动子无甲基化组比较，有甲基化组乳腺癌患者的预后更差。PALB2启动子甲基化作为影响乳腺癌患者预后的独立危险因素，对于评估患者临床预后有着重要意义。
【目的】探討乳腺癌易感基因PALB2啟動子甲基化與乳腺癌臨床病理特徵、預後的關繫。【方法】採用MSP法檢測128例乳腺癌石蠟組織中PALB2啟動子甲基化情況，分析其與乳腺癌臨床病理特徵及臨床預後的相關性。【結果】128例乳腺癌中有淋巴結轉移的患者中14．04％（8／57）檢測齣PALB2啟動子甲基化，高于無淋巴結轉移患者的2．82％（2／71），且差異具有顯著性（ P ＜0．05）。PALB2啟動子甲基化組的中位無瘤生存時間與中位總生存時間分彆為50箇月和51．5箇月，無甲基化組的中位無瘤生存時間與總生存時間分彆為54箇月和88箇月，兩者相比較差異均具有顯著性（ P ＜0．01）。乳腺癌患者預後相關因素分析提示N分期及PALB2啟動子甲基化情況均是影響乳腺癌患者預後的獨立危險因素。【結論】乳腺癌組織PALB2基因啟動子甲基化情況與是否有淋巴結轉移相關。與PALB2啟動子無甲基化組比較，有甲基化組乳腺癌患者的預後更差。PALB2啟動子甲基化作為影響乳腺癌患者預後的獨立危險因素，對于評估患者臨床預後有著重要意義。
【목적】탐토유선암역감기인PALB2계동자갑기화여유선암림상병리특정、예후적관계。【방법】채용MSP법검측128례유선암석사조직중PALB2계동자갑기화정황，분석기여유선암림상병리특정급림상예후적상관성。【결과】128례유선암중유림파결전이적환자중14．04％（8／57）검측출PALB2계동자갑기화，고우무림파결전이환자적2．82％（2／71），차차이구유현저성（ P ＜0．05）。PALB2계동자갑기화조적중위무류생존시간여중위총생존시간분별위50개월화51．5개월，무갑기화조적중위무류생존시간여총생존시간분별위54개월화88개월，량자상비교차이균구유현저성（ P ＜0．01）。유선암환자예후상관인소분석제시N분기급PALB2계동자갑기화정황균시영향유선암환자예후적독립위험인소。【결론】유선암조직PALB2기인계동자갑기화정황여시부유림파결전이상관。여PALB2계동자무갑기화조비교，유갑기화조유선암환자적예후경차。PALB2계동자갑기화작위영향유선암환자예후적독립위험인소，대우평고환자림상예후유착중요의의。
[Objective] PALB2 has been identified as a possible susceptibility gene for breast cancer .And mutation of PALB2 is associated with a high risk of breast cancer .The present study was intended to examine promoter methylation of PALB2 in breast cancer and its relationship with clinicopathological parameters and prognostic value .[Methods] MSP (methylation‐specific PCR) was used to detect the promoter methylation of PLAB2 in paraffin‐embedded breast cancer tissues from 128 cases of breast cancer .Then the relationship be‐tween promoter methylation of PALB2 in breast cancer and clinical prognosis were analyzed .[Results]Among them ,14 .03% of breast cancer patient with lymph node metastasis had promoter methylation of PALB 2 .And it was higher than those without lymph node metastasis (2 .82% ,P =0 .018) .The mean disease‐free survival time and overall survival time of PALB2 promoter methylated patient were 50 and 51 .5 months while those without PALB2 promoter methylation 54 and 88 months respectively .And the differences were statistically significant ( P=0 .003 ,P=0 .003) .N stage and promoter methylation of PALB2 were independent prognos‐tic factors for breast cancer .[Conclusion] The promoter methylation of PALB2 in breast cancer tissue is asso‐ciated with lymph node metastasis .Compared with non‐methylation group ,the patients with promoter methyl‐ation of PALB2 have a lower survival rate .Promoter methylation of PALB2 is an independent prognostic factor in breast cancer patients .
